Replimune Q1 net loss narrows as expenses decline
REPL•Analyst view
The current average analyst rating on the shares is buy, with 7 strong buy or buy recommendations, no hold ratings and 1 sell or strong sell rating.
Wall Street's median 12-month price target for Replimune Group, Inc. is $16.50, about 8.6% above its August 13 closing price of $15.19.
Outlook and trial enrollment
Replimune expects to launch TUDRIQEV in the U.S. within 60 days.
The company said current cash and the recent financing will fund operations for over 12 months.
Replimune is actively enrolling patients in the IGNYTE-3 confirmatory Phase 3 trial for TUDRIQEV.
Q1 loss narrows as expenses decline
Replimune's fiscal first-quarter net loss narrowed year-over-year as expenses declined.
The company reported a Q1 loss per share of $0.72.
